- Welcome and Program Overview
- Navigating the Current Treatment Algorithm for R/R MM
- Overview of current treatment options at first relapse
- New indications and approvals: Optimizing integration into current algorithms
- Monitoring for and managing adverse events
- On the Horizon: Emerging Therapies for R/R MM
- Managed Care Strategies for Patient Engagement, Quality Care, and Optimizing Treatment
Date / Time
Rebecca Gonzalez, PharmD, BCOP
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Bhavesh Shah, RPh, BCOP
Chief Pharmacy Officer
Department of Pharmacy
Boston Medical Center Health System
Join us in Chicago or via simulcast for this live, interactive CPE-certified program led by Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discussing optimal managed care pharmacy approaches for managing patients with relapsed or refractory multiple myeloma.
The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with relapsed/refractory multiple myeloma.
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with relapsed/refractory multiple myeloma as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
Upon completion of this activity, participants should be able to:
- Recognize approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to aid the interprofessional, collaborative care team in treatment decision making using available data and patient-related and disease-related factors
- Develop an understanding of the mechanisms of action of and clinical trial findings with recently FDA-approved novel therapies to facilitate optimal integration into treatment algorithms/clinical pathways
- Assist the interprofessional, collaborative care team in the supportive care of patients with relapsed/refractory multiple myeloma through early detection and management of treatment-related adverse events
- Identify ways managed care pharmacists can promote optimal clinical integration of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to reduce associated costs, decrease hospitalization, and improve outcomes for patients
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-095-L01-P has been assigned to this live application-based activity (initial release date 3-31-2022). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.